Boreal Genomics, a Los Altos, CA-based provider of technology for non-invasive genomic profiling of tumors from blood plasma of cancer patients, completed an $18m Series C financing.
The company intends to use the financing to expand commercial operations in the translational research market and laboratory capabilities and launch clinical applications for non-invasive genomic profiling and monitoring of cancer.
Led by Nitin Sood, CEO, Boreal Genomics provides a platform that performs sensitive genomic analysis of cell-free DNA in plasma to detect and quantify mutations in tumor-derived circulating nucleic acids. The company currently provides the assay through both service and instrument offerings for research use only and expects the test will soon be certified for use in clinical studies.
The company is also expanding their Bay Area facilities, including laboratory and commercial operations at a new location in Mountain View, CA. It also has a research and development site in Vancouver, British Columbia.